Sanofi Statistics
Total Valuation
Sanofi has a market cap or net worth of $111.55 billion. The enterprise value is $128.89 billion.
Important Dates
The last earnings date was Thursday, April 23, 2026, before market open.
| Earnings Date | Apr 23, 2026 |
| Ex-Dividend Date | May 9, 2025 |
Share Statistics
Sanofi has 1.20 billion shares outstanding. The number of shares has decreased by -2.73% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.20B |
| Shares Change (YoY) | -2.73% |
| Shares Change (QoQ) | -0.70% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 47.34% |
| Float | 1.09B |
Valuation Ratios
The trailing PE ratio is 12.81 and the forward PE ratio is 9.24.
| PE Ratio | 12.81 |
| Forward PE | 9.24 |
| PS Ratio | 2.04 |
| Forward PS | 2.29 |
| PB Ratio | 1.32 |
| P/TBV Ratio | 25.99 |
| P/FCF Ratio | 11.10 |
| P/OCF Ratio | 9.36 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 8.72, with an EV/FCF ratio of 12.82.
| EV / Earnings | 14.80 |
| EV / Sales | 2.36 |
| EV / EBITDA | 8.72 |
| EV / EBIT | 11.52 |
| EV / FCF | 12.82 |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.27.
| Current Ratio | 1.01 |
| Quick Ratio | 0.20 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | 1.53 |
| Debt / FCF | 2.30 |
| Interest Coverage | 18.84 |
Financial Efficiency
Return on equity (ROE) is 6.43% and return on invested capital (ROIC) is 9.38%.
| Return on Equity (ROE) | 6.43% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 9.38% |
| Return on Capital Employed (ROCE) | 9.90% |
| Weighted Average Cost of Capital (WACC) | 5.34% |
| Revenue Per Employee | $729,489 |
| Profits Per Employee | $116,385 |
| Employee Count | 74,846 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Sanofi has paid $1.13 billion in taxes.
| Income Tax | 1.13B |
| Effective Tax Rate | 16.83% |
Stock Price Statistics
The stock price has decreased by -12.18% in the last 52 weeks. The beta is 0.32, so Sanofi's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | -12.18% |
| 50-Day Moving Average | 46.38 |
| 200-Day Moving Average | 48.07 |
| Relative Strength Index (RSI) | 42.87 |
| Average Volume (20 Days) | 2,742,414 |
Short Selling Information
The latest short interest is 7.64 million, so 0.63% of the outstanding shares have been sold short.
| Short Interest | 7.64M |
| Short Previous Month | 7.40M |
| Short % of Shares Out | 0.63% |
| Short % of Float | 0.70% |
| Short Ratio (days to cover) | 2.50 |
Income Statement
In the last 12 months, Sanofi had revenue of $54.60 billion and earned $8.71 billion in profits. Earnings per share was $7.15.
| Revenue | 54.60B |
| Gross Profit | 39.51B |
| Operating Income | 11.19B |
| Pretax Income | 6.73B |
| Net Income | 8.71B |
| EBITDA | 14.79B |
| EBIT | 11.19B |
| Earnings Per Share (EPS) | $7.15 |
Full Income StatementBalance Sheet
The company has $6.39 billion in cash and $23.08 billion in debt, giving a net cash position of -$16.69 billion or -$13.86 per share.
| Cash & Cash Equivalents | 6.39B |
| Total Debt | 23.08B |
| Net Cash | -16.69B |
| Net Cash Per Share | -$13.86 |
| Equity (Book Value) | 84.33B |
| Book Value Per Share | 69.71 |
| Working Capital | 179.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $11.92 billion and capital expenditures -$2.03 billion, giving a free cash flow of $10.05 billion.
| Operating Cash Flow | 11.92B |
| Capital Expenditures | -2.03B |
| Depreciation & Amortization | 3.66B |
| Net Borrowing | 1.76B |
| Free Cash Flow | 10.05B |
| FCF Per Share | $8.35 |
Full Cash Flow StatementMargins
Gross margin is 72.36%, with operating and profit margins of 20.49% and 15.95%.
| Gross Margin | 72.36% |
| Operating Margin | 20.49% |
| Pretax Margin | 12.32% |
| Profit Margin | 15.95% |
| EBITDA Margin | 27.09% |
| EBIT Margin | 20.49% |
| FCF Margin | 18.41% |